...
首页> 外文期刊>Leukemia and lymphoma >Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplant.
【24h】

Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplant.

机译:同种异体干细胞移植后患者的多瘤病毒BK特异性CD8 + T细胞反应。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Polyomavirus BK (BKV) is known as an important etiologic agent in the development of hemorrhagic cystitis (HC) after allogeneic stem cell transplant (SCT). To define T cell epitopes of the BKV proteins VP1 and sT, eight potential HLA-A2-binding peptides were synthesized based on computer algorithms. These peptides were co-incubated with CD8 + T cells from the peripheral blood (PB) of 25 healthy volunteers and seven patients suffering from HC after allogeneic SCT in a mixed-lymphocyte peptide culture (MLPC), which were subsequently screened by enzyme-linked immunospot (ELISPOT) assays and fluorescence-activated cell sorting (FACS) analysis. We found that CD8 + T cells from five of seven (71%) patients with HC presensitized with the BKV peptide VP1 p108 (LLMWEAVTV) specifically recognized T2 cells pulsed with VP1 p108. In contrast, only seven of 25 (28%) healthy volunteers had CD8 + T cells reactive with VP1 p108-pulsed T2 cells. The presence of VP1 p108-specific T cells could be confirmed by FACS analysis. The BKV peptide VP1 p108 seems to play an important role as an immunodominant peptide in the pathogenesis of HC in patients after allogeneic SCT, and might be a promising target for immunotherapies or even strategies to prevent the development of BKV-associated HC.
机译:多瘤病毒BK(BKV)是同种异体干细胞移植(SCT)后出血性膀胱炎(HC)发生的重要病因。为了定义BKV蛋白VP1和sT的T细胞表位,基于计算机算法合成了八个潜在的HLA-A2结合肽。将这些肽与来自25名健康志愿者和7名患有HC的患者的外周血(PB)的CD8 + T细胞在同种异体SCT后在混合淋巴细胞肽培养(MLPC)中共同孵育,随后通过酶联筛选免疫斑点(ELISPOT)分析和荧光激活细胞分选(FACS)分析。我们发现,用BKV肽VP1 p108(LLMWEAVTV)预敏的HC患者中,有七名患者中有五名(71%)的CD8 + T细胞能够特异性识别被VP1 p108脉冲的T2细胞。相反,在25位健康志愿者(28%)中,只有7位具有与VP1 p108脉冲T2细胞反应的CD8 + T细胞。 VP1 p108特异性T细胞的存在可以通过FACS分析确认。 BKV肽VP1 p108似乎在异基因SCT后患者的HC发病中作为免疫原性肽起着重要作用,并且可能成为免疫疗法甚至是预防BKV相关HC发生的策略的有希望的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号